- Posted By: TreehillPartners
- In: Dealmaking, Financing & Capital Markets
Proceeds will be used to fund Phase 2 ELAINE clinical trial, which is currently enrolling, to develop lasofoxifene as a potential precision medicine for metastatic breast cancer patients with ESR1 mutations. Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology...
- Posted By: TreehillPartners
- In: Drug Development, Leadership & Restructuring
- Posted By: TreehillPartners
- In: Dealmaking
- Posted By: TreehillPartners
- In: Drug Development, Strategy & Corporate Development